C.-H. Ma, T.-R. Kang, L. He, Q.-Z. Liu
SHORT COMMUNICATION
Supporting Information (see footnote on the first page of this arti-
cle): Experimental procedures, 1H, 19F, and 13C NMR spectra,
HPLC data of 6–8, and crystal data of 6k.
optical purity was observed during the reduction (64%
yield, 90% ee).[15] Saponification of the ester 7a with al-
coholic sodium hydroxide and subsequent acidification gave
the corresponding acid, which was decarboxylated upon
heating in xylene at reflux to afford the corresponding γ-
butyrolactam 8a, with trifluoromethyl and 3-indolyl both
attached to the β-position, in a total yield of 84% over three
steps with no erosion of enantioselectivity (see the Support-
ing Information).[16] Note that the tosyl group was also re-
moved under the base hydrolysis conditions. The GABA
could be easily synthesized from optically enriched 8a ac-
cording to a literature procedure.[17]
Acknowledgments
This work was supported by the National Natural Science Founda-
tion of China (NSFC) (21102116) and the Innovative Research
Team in the College of Sichuan Province (Grant no. 14TD0016).
[1] a) P. Kirsch, Modern Fluoroorganic Chemistry: Synthesis Reac-
tivity, Applications, Wiley-VCH, Weinheim, 2004; b) I. Ojima
(Ed.), Fluorine in Medicinal Chemistry and Chemical Biology,
Wiley, Chichester, 2009.
[2] a) H. Hasegawa, M. Muraoka, K. Matsui, A. Kojima, Bioorg.
Med. Chem. Lett. 2003, 13, 3471–3475; b) P. R. Daga, R. J.
Doerksen, J. Comput. Chem. 2008, 29, 1945–1954; c) W. K.
Hagmann, J. Med. Chem. 2008, 51, 4359–4369; d) R. Filler, R.
Saha, Future Med. Chem. 2009, 1, 777–791; e) H. Xie, Y.
Zhang, S. Zhang, X. Chen, W. Wang, Angew. Chem. Int. Ed.
2011, 50, 11773–11776; Angew. Chem. 2011, 123, 11977–11980.
[3] F. Diederich in Fluorine in Pharmaceutical and Medicinal
Chemistry (Eds.: V. Gouverneur, K. Müller), Imperial College
Press, London, 2012, pp. v–x.
Figure 3. Biologically active pyrrolidinone and GABA analogues.
[4] For recent reviews, see: a) R. J. Lundgren, M. Stradiotto, An-
gew. Chem. Int. Ed. 2010, 49, 9322–9324; Angew. Chem. 2010,
122, 9510; b) T. Furuya, A. S. Kamlet, T. Ritter, Nature 2011,
473, 470–477; c) F.-L. Qing, F. Zheng, Synlett 2011, 1052–1072;
d) S. Roy, B. T. Gregg, G. W. Gribble, V.-D. Le, S. Roy, Tetrahe-
dron 2011, 67, 2161–2195; e) O. A. Tomashenko, V. V. Grushin,
Chem. Rev. 2011, 111, 4475–4521; f) T. Besset, C. Schneider,
D. Cahard, Angew. Chem. Int. Ed. 2012, 51, 5048–5050; Angew.
Chem. 2012, 124, 5134.
[5] a) E. J. Corey, A. Guzman-Perez, Angew. Chem. Int. Ed. 1998,
37, 388–401; Angew. Chem. 1998, 110, 2092; b) C. J. Douglas,
L. E. Overman, Proc. Natl. Acad. Sci. USA 2004, 101, 5363–
5367; c) J. Christoffers, A. Baro, Adv. Synth. Catal. 2005, 347,
1473–1482; d) B. M. Trost, C. Jiang, Synthesis 2006, 369–396;
e) C. Hawner, A. Alexakis, Chem. Commun. 2010, 46, 7295–
7306.
Scheme 2. Synthetic transformation of the Michael addition prod-
ucts. Reagents and conditions: (a) NiCl2·6H2O, NaBH4/MeOH,
0 °C to room temp., 20 h; (b) 6 n NaOH/EtOH, 45 °C, 24 h; (c) 6 n
HCl, pH Ͻ 1; (d) xylene, 150 °C, 12 h.
[6] For selected reviews, see: a) O. M. Berner, L. Tedeschi, D. En-
ders, Eur. J. Org. Chem. 2002, 1877–1894; b) J. Aleman, A.
Milelli, S. Cabrera, E. Reys, K. A. Jorgensen, Chem. Eur. J.
2008, 14, 10958–10966; c) A. J. M. Barrett, Chem. Soc. Rev.
1991, 20, 95–127; d) D. A. Evans, S. Mito, D. Seidel, J. Am.
Chem. Soc. 2007, 129, 11583–11592; e) A. J. M. Barrett, G. G.
Graboski, Chem. Rev. 1986, 86, 751–762; f) R. Marcia de Fig-
ueiredo, M. Christmann, Eur. J. Org. Chem. 2007, 2575–2600;
g) P. I. Dalko, L. Moisan, Angew. Chem. Int. Ed. 2004, 43,
5138–5175; Angew. Chem. 2004, 116, 5248.
[7] For selected examples, see: a) J.-R. Gao, H. Wu, B. Xiang, W.-
B. Yu, L. Han, Y.-X. Jia, J. Am. Chem. Soc. 2013, 135, 2983–
2986; b) J. Wu, D. M. Mampreian, A. H. Hoveyda, J. Am.
Chem. Soc. 2005, 127, 4584–4585; c) F.-L. Liu, J. R. Chen, B.
Feng, X.-Q. Fu, L.-H. Ye, L.-Q. Lu, W.-J. Xiao, Org. Biomol.
Chem. 2014, 12, 1057–1060; d) Y.-L. Liu, T.-D. Shi, F. Zhou,
X.-L. Zhou, X. Wang, J. Zhou, Org. Lett. 2011, 13, 3826–3829;
e) P. Melchiorre, M. Marigo, A. Carlone, G. Bartoli, Angew.
Chem. Int. Ed. 2008, 47, 6138–6171; Angew. Chem. 2008, 120,
6232.
[8] For selected reviews on chiral thiourea catalysis, see: a) Y. Take-
moto, Org. Biomol. Chem. 2005, 3, 4299–4306; b) Y. Takemoto,
Chem. Pharm. Bull. 2010, 58, 593–601; c) S. J. Connon, Chem.
Eur. J. 2006, 12, 5418–5427; d) M. S. Taylor, E. N. Jacobsen,
Angew. Chem. Int. Ed. 2006, 45, 1520–1543; Angew. Chem.
2006, 118, 1550; e) X. H. Yu, W. Wang, Chem. Asian J. 2008,
3, 516–532; f) S. J. Connon, Chem. Commun. 2008, 2499–2510;
g) O. V. Serdyuk, C. M. Heckel, S. B. Tsogoeva, Org. Biomol.
Conclusions
We have developed an enantioselective Michael addition
reaction between malonates and β-CF3-β-(3-indolyl)nitro-
alkenes that affords γ-nitrobutyric acid esters bearing an
all-carbon quaternary stereogenic centre in moderate to
high yields and with good to excellent enantioselectivities.
The Michael products can also be conveniently transformed
into the optically enriched γ-butyrolactams and γ-amino-
butyric acids.
Experimental Section
General Procedure for the Asymmetric Michael Addition Reactions:
A thiourea catalyst (20 mol-%), malonate (1 mmol), and AcONa
(80 mol-%) were added to a solution of β-CF3-β-(3-indolyl)nitroal-
kene (0.05 mmol) in toluene (0.5 mL) at room temperature. The
reaction mixture was stirred at room temperature until the reaction
was complete (monitored by TLC) and then purified by flash col-
umn chromatography on silica gel (petroleum ether/ethyl acetate,
50:1 to 10:1) to yield γ-nitrobutyric acid esters 6a–6p.
3984
www.eurjoc.org
© 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Eur. J. Org. Chem. 2014, 3981–3985